Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Primary Purpose
Hand Dermatoses
Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
alitretinoin
Sponsored by
About this trial
This is an interventional treatment trial for Hand Dermatoses focused on measuring Hand Dermatoses,, hand dermatitis, hand eczema, chronic hand dermatitis, retinoid
Eligibility Criteria
Inclusion Criteria: Chronic hand dermatitis, rated as severe by physicians global assessment, present for at least 6 months, that has not responded to the avoidance of allergens and irritants and the use of topical steroids Exclusion Criteria: female of childbearing potential, unless participating in a pregnancy prevention program psoriasis active major psychiatric condition
Sites / Locations
- Abt. Klinische Sozialmedizin
Outcomes
Primary Outcome Measures
Safety:
Adverse Events
Safety Laboratory
Radiological investigations (bone density, x-ray)
Secondary Outcome Measures
Physicians Global Assessment
modified Total Lesion Symptom Score
Patients Global Assessment
Patient Defined Outcomes
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00309621
Brief Title
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
Official Title
Safety and Efficacy of Alitretinoin in the Treatment of Severe Refractory Chronic Hand Dermatitis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
May 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Basilea Pharmaceutica
4. Oversight
5. Study Description
Brief Summary
Patients with severe chronic hand dermatitis, that has not responded to topical treatment, including topical steroids and the avoidance of aggravating factors, will be treated with the oral medication alitretinoin. The study aims to investigate the safety and efficacy of the medication when given over a period of 6 months.
Detailed Description
For severe, chronic hand dermatitis, refractory to topical treatment and the avoidance of aggravating factors such as allergens and irritants, no registered systemic treatment is available. Current systemic treatment options consist in the off-label use of systemic immune suppressants, such as cyclosporine, methotrexate.
Severe chronic hand dermatitis is a debilitating disease, with massive impact on social life and working ability. A huge proportion of the population suffers for more than a decade, and job losses are a frequent consequence.
This open-label trial investigates the safety and efficacy of oral alitretinoin 30mg as a single daily dose for up to 6 months. The trial is complementary to the pivotal efficacy study BAP00089.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand Dermatoses
Keywords
Hand Dermatoses,, hand dermatitis, hand eczema, chronic hand dermatitis, retinoid
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
250 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
alitretinoin
Primary Outcome Measure Information:
Title
Safety:
Title
Adverse Events
Title
Safety Laboratory
Title
Radiological investigations (bone density, x-ray)
Secondary Outcome Measure Information:
Title
Physicians Global Assessment
Title
modified Total Lesion Symptom Score
Title
Patients Global Assessment
Title
Patient Defined Outcomes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic hand dermatitis, rated as severe by physicians global assessment, present for at least 6 months, that has not responded to the avoidance of allergens and irritants and the use of topical steroids
Exclusion Criteria:
female of childbearing potential, unless participating in a pregnancy prevention program
psoriasis
active major psychiatric condition
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Diepgen, MD
Organizational Affiliation
Univ. Heidelberg
Official's Role
Principal Investigator
Facility Information:
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G2G3
Country
Canada
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5O3Y1
Country
Canada
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3C1R4
Country
Canada
City
Hawkesbury
State/Province
Ontario
ZIP/Postal Code
K6A1A1
Country
Canada
City
London
State/Province
Ontario
ZIP/Postal Code
N6H1S9
Country
Canada
City
Markham
State/Province
Ontario
ZIP/Postal Code
L3P1A8
Country
Canada
City
Oakville
State/Province
Ontario
ZIP/Postal Code
L6J7W5
Country
Canada
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3X1V6
Country
Canada
City
Sheerbroke
State/Province
Quebec
ZIP/Postal Code
J1H1Z1
Country
Canada
City
Quebec
ZIP/Postal Code
G1J1X7
Country
Canada
City
Berlin
ZIP/Postal Code
12353
Country
Germany
City
Berlin
ZIP/Postal Code
13439
Country
Germany
City
Frankfurt
ZIP/Postal Code
60326
Country
Germany
City
Hamburg
ZIP/Postal Code
20246
Country
Germany
City
Hamburg
ZIP/Postal Code
20354
Country
Germany
City
Hamburg
ZIP/Postal Code
22143
Country
Germany
Facility Name
Abt. Klinische Sozialmedizin
City
Heidelberg
ZIP/Postal Code
69115
Country
Germany
City
Ibbenbüren
ZIP/Postal Code
49477
Country
Germany
City
Köln
ZIP/Postal Code
51143
Country
Germany
City
Lübeck
ZIP/Postal Code
23558
Country
Germany
City
Mönchengladbach
ZIP/Postal Code
41061
Country
Germany
City
München
ZIP/Postal Code
81375
Country
Germany
City
Münster
ZIP/Postal Code
48143
Country
Germany
City
Osnabrück
ZIP/Postal Code
49078
Country
Germany
City
Potsdam
ZIP/Postal Code
14482
Country
Germany
City
Viersen
ZIP/Postal Code
41747
Country
Germany
City
Wuppertal
ZIP/Postal Code
42275
Country
Germany
City
Gdansk
Country
Poland
City
Krakow
ZIP/Postal Code
31-462
Country
Poland
City
Lublin
Country
Poland
City
Opole
ZIP/Postal Code
45-372
Country
Poland
City
Szcecin
Country
Poland
City
Wroclaw
Country
Poland
12. IPD Sharing Statement
Citations:
PubMed Identifier
15611422
Citation
Ruzicka T, Larsen FG, Galewicz D, Horvath A, Coenraads PJ, Thestrup-Pedersen K, Ortonne JP, Zouboulis CC, Harsch M, Brown TC, Zultak M. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004 Dec;140(12):1453-9. doi: 10.1001/archderm.140.12.1453.
Results Reference
background
PubMed Identifier
19659963
Citation
Blome C, Maares J, Diepgen T, Jeffrustenbach S, Augustin M. Measurement of patient-relevant benefits in the treatment of chronic hand eczema--a novel approach. Contact Dermatitis. 2009 Jul;61(1):39-45. doi: 10.1111/j.1600-0536.2009.01536.x.
Results Reference
derived
Learn more about this trial
Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis
We'll reach out to this number within 24 hrs